

# **Amit G Patel & Associates**

**Chartered Accountants** 

# INDEPENDENT AUDITOR'S REPORT

To,
The Members,
SOTAC HEALTHCARE PRIVATE LIMITED
CIN -U369992019PTC106282

# Opinion

We have audited the financial statements of **SOTAC HEALTHCARE PRIVATE LIMITED CIN- U369992019PTC106282** ("the Company"), which comprise the balance sheet as at 31st March 2022, and the statement of profit and loss, (statement of changes in equity) and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit/loss, (changes in equity) and its cash flows for the year ended on that date.

# **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

# Other Information

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

# Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## Other Matter

Our opinion is not modified in respect of this matter.

# Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2020 (the Order) issued by the Central government of India in terms of sub-section (11) of Section 143 of the Act, we give in the Annexure a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

- (c) The Balance Sheet, the Statement of Profit and Loss, (the Statement of Changes in Equity) and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164(2) of the Act.
- (f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - 1. The Company does not have any pending litigations which would impact its financial position
  - 2. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - 3. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company
- 2. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143(11) of the Act, we give in 'Annexure A'.

M.No. 197675 FRN No. 152837W For Amit G Patel & Associates Chartered Accountants Firm Reg.No.0152837W

CA Amit G Patel (Proprietor)

Membership No. 173586 UDIN:22197675AWVUYE3101

Place: Ahmedabad Date: 02/09/2022

# ANNEXURE 'A' TO THE INDEPENDENT AUDITORS' REPORT (Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government in terms of Section 143(11) of the Companies Act, 2013 ('the Act') of SOTAC HEALTHCARE PRIVATE LIMITED CIN-U369992019PTC106282 ('the company')

- 1. In respect of the Company's Property, Plant and Equipment:
  - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property , Plant and Equipment and Intangible Assets.
  - (b) The Property , Plant and Equipment were physically verified during the year by the Management in accordance with a regular programme of verification which, in our opinion, provides for physical verification of all the Property , Plant and Equipment at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
  - (c) According to the information and explanations given to us and the records examined by us and based on the examination of the Title deeds of the all the Immovable Properties are in the name of the Company.
  - (d) The company has not revalued its Property, Plant and Equipment.
  - (e) According to the information and explanations given to us, there is no any proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under,
- 2. (a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on physical verification.
  - (b) The Company has been sanctioned working Capital limits in excess of five crores, in aggregate, from banks on the security of current assets and the quarterly returns or statements filed by the

company with such banks are in agreement with the books of account of the Company.

- 3. During the year the company has not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties, hence Claus 3 (iii) (a to f) are not applicable. –
- 4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.
- 5. In our opinion and according to the information and explanations given to us, The Company has accepted deposits during the year and does have unclaimed deposits as at March 31, 2022 the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act and the rules made thereunder,
- 6. Reporting under clause 3(vi) of the Order is not applicable as the Company's business activities are not covered by the Companies (Cost Records and Audit) Rules, 2014.
- 7. In our opinion and according to the information and explanations given to us, in respect of statutory dues:
  - a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Value Added Tax, duty of Customs, duty of Excise, Cess and other material statutory dues applicable to it with the appropriate authorities Except

Following Undisputed dues are not deposited:

Type of Dues	Amount (Rs.)	
Professional Tax	45,730/-	

b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Value Added Tax, duty of Customs, duty of Excise, Cess and other material statutory dues in arrears as at

March 31, 2022 for a period of more than six months from the date they became payable.

- 8. In our opinion and according to the information and explanations given to us, there is no any transactions which are not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961), hence reporting under clause 3(xiii) of the Order is not applicable.
- 9. (a) In our opinion and according to the information and explanations given to us, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender, hence reporting under clause 3(ix)(a) of the Order is not applicable.
  - (b) In our opinion and according to the information and explanations given to us, the company is a declared wilful defaulter by any bank or financial institution or other lender, hence reporting under clause 3(ix)(b) of the Order is not applicable.
  - (c) In our opinion and according to the information and explanations given to us, term loans were applied for the purpose for which the loans were obtained, hence reporting under clause 3(ix)(c) of the Order is not applicable.
  - (d) According to the information and explanations given to us There is no funds raised, hence reporting under clause 3(ix)(d) of the Order is not applicable.
  - (e) In our opinion and according to the information and explanations given to us, The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures, hence reporting under clause 3(ix)(e) of the Order is not applicable.
  - (f) In our opinion and according to the information and explanations given to us, The company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies, hence reporting under clause 3(ix)(f) of the Order is not applicable.
- 10. In our opinion and according to the information and explanations given to us, There is no moneys raised by way of initial public offer or further public offer (including debt instruments) or any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the treat, hence reporting under clause 3(x) of the Order is not applicable 1875.

- 11. (a) In our opinion and according to the information and explanations given to us, There is no any fraud by the company or any fraud on the company has been noticed or reported during the year, hence reporting under clause 3(xi)(a) of the Order is not applicable.
  - (b) No any report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government; , hence reporting under clause 3(xi)(b) of the Order is not applicable.
  - (c) The Auditor has not considered whistle-blower complaints, hence reporting under clause 3(xi)(c) of the Order is not applicable.
- 12. The Company is not Nidhi Company, hence reporting under clause 3(xii) (a),(b) and (c) of the Order is not applicable.
- 13. In our opinion and according to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act where applicable and the details have been disclosed in the financial statements, etc., as required by the applicable accounting standards;
- 14. (a) In our opinion and according to the information and explanations given to us, The Provisions of Internal Audit under section 138 is not applicable to the Company, hence reporting under Clause 3(xiv)(a) is not applicable. The company has an internal Control system commensurate with the size and nature of its business; and
  - (b) The Provisions of Internal Audit under section 138 is not applicable to the Company, hence reporting under Clause 3(xiv)(b) is not applicable.
- 15. In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him.
- 16. (a) In our opinion and according to the information and explanations given to us, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934), , hence reporting under Clause 3(xi)(a) is not applicable.
  - (b) In our opinion and according to the information and explanations given to us, the company has not conducted any Non-Banking Financial or Housing Finance activities, hence reporting under Clause 3(xi)(b) is not applicable.

- (c) In our opinion and according to the information and explanations given to us, the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, , hence reporting under Clause 3(xi)(c) is not applicable.
- (d) In our opinion and according to the information and explanations given to us, The Company is neither Group or CIC, hence reporting under Clause 3(xi)(d) is not applicable.
- 17. In our opinion and according to the information and explanations given to us, the company has not incurred cash losses in the financial year and the Company has incurred Cash Losses of (Rs. 2,09,38,674/-) in the immediately preceding financial year 2020-21,
- 18. In our opinion and according to the information and explanations given to us, there has not been any resignation of the statutory auditors during the year, hence reporting under Clause 3(xiii) is not applicable.
- 19. In our opinion and according to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, We have opinioned that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date;
- 20. (a) In our opinion and according to the information and explanations given to us, in respect of other than ongoing projects, as at balance sheet date, the Section 135(5) of the Act is not applicable to the Company. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable.
  - (b) In our opinion and according to the information and explanations given to us, in respect of ongoing projects, as at balance sheet date, the Section 135(5) of the Act is not applicable to the Company, Accordingly, reporting under clause 3(xx)(b) of the Order is not applicable.

21. In our opinion and according to the information and explanations given to us, The Company does not have any subsidiary/Join ventures/Associate Company, Accordingly, reporting under clause 3(xxi) of the Order is not applicable

M.No. 197675 RN No. 152837V A'BAD

Date:02/09/2022 Place: Ahmedabad For, Amit G Patel & Associates Chartered Accountants FRN: 152837W

CA Amit G Patel

Proprietor

Mem No: 197675

UDIN: 22197675AWVUYE3101

# SOTAC HEALTHCARE PRIVATE LIMITED BALANCE SHEET AS AT 31ST MARCH, 2022

Plot No PF-20, Sanand GIDC-II,Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

Particulars	Sch. No.	31.03.2022	31.03.2021
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	1	57,150,000	40,000,000
(b) Reserves and Surplus	2	(36,775,906)	(43,131,761)
(c) Money Received Against Share Warrants			1,30
(2) Share Application Money Pending Allotment			
(3) Non-Current Liabilities			
(a) Long-Term Borrowings	3	108,626,431	133,524,294
(b) Deferred Tax Liabilities (Net)	4	1,510,937	-
(c) Other Long Term Liabilities	5		
(d) Long Term Provisions	6	-	-
(4) Current Liabilities			
(a) Short-Term Borrowings	7		-
(b) Trade Payable	8	118,085,547	27,030,336
(c) Other Current Liabilities	9	705,630	118,881
(d) Short-Term Provisions	10	556,331	588,030
Tot	a!	249,858,970	158,129,780
II.ASSETS			
(1) Non-Current Assets			
Property, Plant & Equipment & Intengible Assets	11		
(i) Property, Plant & Equipment		108,226,364	100,202,171
(ii) Intengible Assets			-
(iii) Capital work In -Progress			
(iv) Intengible Assets under Development		*	
(b) Non-Current Investments	12	-	
(c) Deferred Tax Assets (Net)	13		
(d) Long Term Loans and Advances	14	5,093,628	5,293,642
(e) Other Non-Current Assets	15		-
(2) Current Assets			
(a) Inventories	16	37,826,620	10,305,356
(b) Trade Receivables	17	61,636,248	16,165,503
(c) Cash and Cash Equivalents	18	364,040	2,460,451
(d) Short-Term Loans And Advances	19	36,493,325	23,650,366
(e) Other Current Assets	20	218,745	52,291
Significant Policies Tot	30	249,858,970	158,129,780

NOTES TO ACCOUNTS

31
Schedules referred to above and notes attached there to form an integral part of Balance Sheet

This is the Balance Sheet referred to in our Report of even date.

For, AMIT G PATEL & ASSOCIATES

CHARTERED ACCOUNTANTS

CA AMIT G PATEL
Proprietor

Membership No. : 1976157 Firm Reg. No.: 152837W UDIN :22197675AWVUYE3101

M. No. 197675 RN No. 152837W

or, SOTAC HEALTHCARE PRIVATE LIMITED

SHARAD PATEL Director

KAMLESH PATEL Director

Din No-07252252 Din No-08343809 PLACE : AHMEDABAD DATE : 02/09/2022

# SOTAC HEALTHCARE PRIVATE LIMITED

# PROFIT & LOSS STATEMENT FOR THE PERIOD ENDED ON 31ST MARCH,2022

Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

Sr. No	Particulars	Sch.	No.	31.03.2022	31.03.2021
,	Revenue from operations	21		228,537,539	56,855,696
	Other Income	22		13,358,219	142,552
III		otal Income (I +II)		241,895,758	56,998,248
	Expenses:		1		
	Cost of Material Consumed	23	3	219,879,941	67,264,557
- 1	Purchase of Stock in Trade	24		-	-
- 1	Changes in inventories of finished goods, wor				
- 1			.	(27 524 264)	(10,305,356)
- 1	Stock-in-Trade	25		(27,521,264)	
	Employee Benefit Expense	26		7,567,967	2,345,674
	Financial Costs	27		11,249,105	7,675,744
i	Depreciation and Amortization Expense	28		6,166,197	15,935,604
	Other total Expenses	29	,	16,687,020	10,956,303
		otal Expenses (IV)		234,028,966	93,872,526
٧	Profit before exceptional and extraordinary it	tems and tax (III -	IV)	7,866,792	(36,874,278)
VI	Exceptional Items				
VII	Profit before extraordinary items and tax (V -	VI)		7,866,792	(36,874,278)
VIII	Extraordinary Items				
ıx	Profit before tax (VII - VIII)			7,866,792	(36,874,278)
х	Tax expense:				
	(1) Current tax				-
	(2) Deferred tax			1,510,937	•
ΧI	Profit(Loss) from the perid from continuing o	perations (IX	-X)	6,355,855	(36,874,278)
XII	Profit/(Loss) from discontinuing operations				
XIII	Tax expense of discounting operations				
XIV	Profit/(Loss) from Discontinuing operations (	XII - XIII)		-	
xv	Profit/(Loss) for the period (XI + XIV)			6,355,855	(36,874,278
AA	Trong (1000) for the period (n. 1 hrs.)				
XVI	Earning per equity share:				1
	(1) Basic			1.11	(9.22
	(2) Diluted			1.11	(9.22

Schedules referred to above and notes attached there to form an integral part of Profit & Loss Statement This is the Profit & Loss Statement referred to in our Report of even date.

For, AMIT G PATEL & ASSOCIATES

CHARTERED ACCOUNTANTS

CA AMIT G PATEL

Proprietor

Membership No.: 197675 Firm Reg. No.: 152837W UDIN:22197675AWVUYE3101

M.No. 197675 FRN No. 152837W A'BAD For, SOTAC HEALTHCARE PRIVATE LIMITED

SHARAD PATEL Director KAMLESH PATEL

Director Director
Din No-07252252 Din No-08343809

PLACE: AHMEDABAD

DATE:

SOTAC HEALTHCARE PRIVATE LIMITED Plot No PF-20, Sanand GIDC-II,Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

#### Cash Flow Statement for the year ended on 31st March, 2022 Particulars 31st March 2022 31st March 2021 Cash Flow from Operating Activities Net Profit before tax paid 7,866,792 (36,874,277) Adjustments for: Depreciation and amortization 6,166,197 15,935,604 Interest income (111,096)(142,552) Finance Cost 11,249,105 7,675,744 Operating profit before working capital changes (13,405,481) 25,170,998 (a) Adjustments for Working Capital: Increase in Trade Payables 91.055.211 12.826,407 Increase in Other current Liability 586,749 117,962 Decrease of Short term Provisions (31,699) 513,030 (10,305,356) (27,521,264) Increase in Inventories Increase in Trade Receivables (45,470,745) (16,165,503) 181,419 (12,842,959) Increase in Short Term Loans and Advances Increase of Other current assets (166,454) (52,291) 5,608,839 (12,884,332) (b) 30,779,837 (26,289,813) Cash generated from Operations (a+b) Taxes paid ( net of refund) Net Cash generated from Operations (A) 30,779,837 (26,289,813) Cash Flow from Investing Activities (14,241,815) (20,405,568) Addition in Property , Plant and Equipment Interest income 111,096 142,552 (5,293,642) 200,014 Decrease in of Loans and advacnes Disposal of Prperty, Plant and Equipment 51,425 60,403 Net Cash generated / ( used ) in Investing Activities (13,879,280) (25,496,255) (B) Cash Flow from Financing Activities 40,131,015 Repayment in Long term Borrowings (24,897,863) 17,150,000 Issue of New Equity shares 17,900,000 Increase in Short term Borrowings (11,249,105) (7,675,744) Finance Cost paid (18,996,968) 50,355,271 Net Cash Used in Financing Activities (C) (A+B+C) (1,430,797) Net Increase in Cash and Cash Equivalents (2,096,411) 3.891.247 Cash and Cash Equivalents as on 1st April, 2021 2,460,450 Cash and Cash Equivalents as on 31st March, 2022 364,040 2,460,450

As per our attached report of even date

For, AMIT G PATEL & ASSOCIATES

For, SOTAC HEALTHCARE PRIVATE LIMITED

CHARTERED ACCOUNTANTS

M.No. 197675

A'BAD

EDACS

SHARAD PATEL

Director Din No-07252252 KAMLESH PATEL Director Din No-08343809

PLACE: AHMEDABAD DATE: 02/09/2022

CA AMIT G PATEL

Proprietor

Membership No.: 197675

Firm Reg. No.: 152837W

UDIN:22197675AWVUYE3101

#### SOTAC HEALTHCARE PRIVATE LIMITED

Schedules Forming IntegralPart Of Balance Sheet as at 31st March 2022

Schedule: 1 Share Capital

Sr. No	Particulars	31.03.2022	31.03.2021
1	AUTHORIZED CAPITAL		
	75,00,000 Equity Shares of Rs. 10/- each.	75,000,000	40,000,000
		75,000,000	40,000,000
2	ISSUED , SUBSCRIBED & PAID UP CAPITAL		
	To the Subscribers of the Memorandum		
	57,15,000 Equity Shares of Rs. 10/- each.	57,150,000	40,000,000
	Total in	57,150,000	40,000,000

The details of share holders holding more than 5% of shares as at 31st March, 2022 are as follows:

Sr. No.	Name of the Share Holder	As at 31St March	1, 2022
		No. of Shares	% Held
	Mukeshbhai G. Patel	1,500,000	26.25%
	2 Kamleshbhai Patel	1,500,000	26.25%
	Kiranben B. Jotania	367,200	6.43%
	4 Sharadkumar Dashrathbhai Patel	362,712	6.35%
	5 Vishalkumar Devrajbhai Patel	362,712	6.35%
1	5 Dineshkumar Babulal Gelot	362,712	6.35%
	7 Sanket Chandrakantbhai Patel	375,000	6.56%
	Chetankumar Bachubhai Patel	270,912	4.47%

Sr. No.	Name of the Share Holder	As at 31St March, 2021		
	Name of the share holder	No. of Shares 9	% Held	
	1 Sotac Pharmaceuticals Private Ltd	2,040,000	51.00%	
	2 Mukeshbhai G. Patel	800,000	20.00%	
	3 Kamleshbhai Patel	800,000	20.00%	
	4 Sanket Patel	200,000	5.00%	

The details of Holding of the Promotersas at 31st March, 2022 are as follows:

Sr. No.	Name of the Promoter	As at 31St March, 2022		% Change during the Year	
		No. of Shares % Held			
1	Sotac Pharmaceuticals Private Ltd	-	0.00%	-100.00%	
2	Mukeshbhai G. Patel	1,500,000	26.25%	6.25%	
3	Kamleshbhai Patel	1,500,000	26.25%	6.25%	
4	Sanket Chandrakantbhai Patel	375,000	6.56%	1.56%	





Šr. No.	Name of the Promoter	As at 31St March, 2021		% Change during the Year
		No. of Shares	% Held	
1	Sotac Pharmaceuticals Private Ltd	2,040,000	51.00%	NII
2	Mukeshbhai G. Patel	800,000	20.00%	Nil
3	Kamleshbhai Patel	800,000	20.00%	Nil
4	Sanket Patel	200,000	5.00%	Nil

# Statement of changes in Equity

Sr. No	Particulars	31.03.2022	31.03.2021
1	Opening Paid up Equity share capital	40,000,000	40,000,000
2	Equity share capital issued during the year	17,150,000	
3	Closing Balance of Paid up Equity share capital	57,150,000	40,000,000







Schedule: 2 Reserve & Surplu

Sr. No	Particulars	31.03.2022	31.03.2021
1	Balance in Statement of Profit & Loss Balance as at the beginning of the year Add: Current Year Profit Less: Current Year Loss	(43,131,761) 6,355,855	(6,257,483) - (36,874,278)
В	Balance as at the beginning of the year	(36,775,907)	(43,131,761)
2	Security Premium		
	Balance as at the beginning of the year	- 1	
	Add : Securities premium credited on Share issue		
Balan	Balance as at the end of the year		
	Total in	(36,775,907)	(43,131,761)

Sr. No	Particulars		31.03.2022	31.03.2021
1	Secured: Term Loan From Bank: State Bank of India - Term Loan 871 Axis Bank-Term Loan-921060055322696 Axis Bank-Term Loan-921060055322706 SBI Covid Loan-19 State Bank of India - CC A/C-534 Axis Bank C C-24091 Term Loan From NBFC:		33,499,706 6,180,134	46,493,742 8,956,182 21,383,732
		Sub Total (a)	71,885,794	76,333,656
2	Unsecured:			
	From Directors			
	Mukesh G Patel		1 000 000	0.000.000
	Kamlesh Patel		1,800,000	9,000,000
	From Shareholders			
	Sotac Pharmaceuticals Pvt Ltd.		17,140,637	17,140,637
	Sanket Patel			1,750,000
	Akshesh 8 Patel		4	1,000,000
	Hardikbhai		800,000	1,400,000
	Pragnatien Patel			1,000,000
	From Related Parties			
	Narmadaben D Patel		5,900,000	2,000,000
	Chetanbhai Prahaladbhai Patel			8,000,000
	Patel Manishkumar Madhubhai-HUF			1,200,001
	Sarojben Prahaladbhai Patel		2,000,000	2,000,000
	Shantaben Madhubhai Patel			2,000,000
	Smeet Manishkumar Patel		-	700,000
	Bhavnaben Manishbhai Patel		2,000,000	2,000,000
	Babubhai Mali		1,000,000	
-	Dasharathbahi Rambhai Patel		4,100,000	
	Kalpeshkumar Babulal		500,000	
	Varshaben Kapilkumar Solanki		1,000,000	
	Tejaleben Babubhai Mali		500,000	
		Sub Total (b)	36,740,637	56,690,638
	Total in (a+b)		108,626,431	133,524,294

Note: The Cash Credit Account Facility with the Axis Bank is considered as "Long Term Sorrowing" in view of the bundled credit facilities (other Term Loans) from the Axis Bank.

Schedule : 4 Deferred Tax Liabilities (Net

Sr. Ho	Particulars		31.03.2022	31.03.2021
	Deferred Tax Liability Related to Fixed Assets/ Loss Carreid Forward Deferred tax liability For the year		1,510,937.00	
		.Sub Total (a)	1,510,937.00	
	Deferred Tax Assets			
	Provision For Disallowance of Expenses Nil	i		
	Land to the second second	Sub Total (b)	0	0
	Net Deffered Tax Liabilites (a-b)		1,510,937	

> M No. 197673 ERN NO. 152837W A EAD
>
> OFFED ACCOMP

Soft

CHIMAN SOL

Schedule : 6 Lone Term Provision

Sr. No	Particulars	31.03.2022	31.03.2021
	NII		
Total in			

Schedule: 7 Short Term Barrowing

Sr. No	Particulars	31.03.2022	31.03.2021
	Nil		
Total in			

Schedule: 8 Trade Pavable

Sr. No	Total in	31.03.2022	31.03.2021
1	As per Annexture A	118,085,547	27,030,336
	Total in	118,085,547	27,030,336

Schedule :9 Other Current Liabilities

Sr. No	Total In	31.03.2022	31.03.2021
3	TDS Payable	743	61,073
2	TCS Payable	609,005	322
3	ESIC Payable	11,596	9,934
4	PF Payable	30,072	31,006
5	RCM Payable	8,484	16,546
5	Professional Tax Payable	45,730	
	Total in	705,630	118,881

Schedule: 10 Short Term Provisions

Sr. No	Particulars 31.03.2022		31.03.2021	
1	Provision for Audit fees	100,000	259,979	
2 Salary Payable	Salary Payable	456,331	328,051	
	Total in	556,331	588,030	

Sr. No	Particulars	31.03.2022	31.03.2021
	Tangible Assets		
	Building		
	Gross Block at the begening of the year	22,215,513	20,053,630
	Additions	2,173,159	2,161,883
	Deletion		
	Total Gross Block at the end of the year	24,388,672	22,215,513
	Less:		
	Accumulated Depreciation at the begening of the year	2,593,296	2,493,000
	Additions to Depreciation during the year	690,829	100,294
	Accumulated Depreciation at the end of the year	3,284,125	2,593,296
	Net Block	21,104,547	19,622,217
	Computer & Printer		
	Gross Block at the begening of the year	721,922	49,99
	Additions	131,387	694,82
	Deletion		(22,900
	Total Gross Block at the end of the year	853,309	721,92
	Less:		
	Accumulated Depreciation at the begening of the year	231,009	39,643
	Additions to Depreciation during the year	195,638	191,36
	Accumulated Depreciation at the end of the year	426,647	231,009
	Net Block	426,662	490,933
	Electric & Fitting		
	Gross Block at the begening of the year	3,624,340	1,167,83
	Additions	303,067	2,456,50
	Deletion	(51,425)	
	Total Gross Block at the end of the year	3,875,982	3,624,34
	Less:		
	Accumulated Depreciation at the begening of the year	481,234	314,70
	Additions to Depreciation during the year	324,014	166,52
	Accumulated Depreciation at the end of the year	805,248	481,23
	Net Block	3,070,734	3,143,10



Of 2

1101 270 08		
Accumulated Depreciation at the end of the year Net Block		
Additions to Depreciation during the year		-
Accumulated Depreciation at the begening of the year		
Less:		
Total Gross Block at the end of the year		
Deletion		
Gross block at the begening of the year Additions		
intengible Assets under Development Gross Block at the begening of the year		
Internation Names and a Parintage of		
Net Block		
Accumulated Depreciation at the end of the year	- 1	-
Additions to Depreciation during the year	-	
Accumulated Depreciation at the begening of the year	•	
Less:		
Total Gross Block at the end of the year	- 1	
Deletion	-	
Additions		
Gross Block at the begening of the year		
Capital Work in Progress		
TEL MOLE		
Accumulated Depreciation at the end of the year Net Block		
Additions to Depreciation during the year		
Accumulated Depreciation at the begening of the year		
Less;		
Total Gross Block at the end of the year	_	
Deletion	-	
Additions	*	-
Gross Block at the begening of the year	-	
Software		
	200,220,333	
Total Yangible Assets	108,225,364	
105 0000	63,033,280	30,103,31
Net Block	65,099,288	58,789,51
Accumulated Depreciation at the end of the year	19,408,407	15,014,95
Additions to Depreciation during the year	4,393,452	1,148,51
Accumulated Depreciation at the begening of the year	15,014,955	13,866,44
Less:	7	,,
Total Gross Block at the end of the year	84,507,695	73,804,47
Deletion	10,703,225	3,04,02
Additions	10,703,225	9,094,52
Gross Block at the begening of the year	73,804,470	64,709,94
Plant & Machinery		
THE SHOULD	13,126,000	13,126,00
Accumulated Depreciation at the end of the year Net Block	13 136 000	12 150 00
Accumulated Depreciation at the end of the year		
Additions to Depreciation at the begening or the year		
less: Accumulated Depreciation at the begening of the year		
Total Gross Block at the end of the year Less:	13,126,000	13,126,00
Deletion	2227 227	******
Additions		
Gross Block at the beginning of the year	13,126,000	13,126,00
Plot		
Net Block	5,399,133	5,030,42
Accumulated Depreciation at the end of the year	1,495,772	933,50
Additions to Depreciation during the year	562,264	932,39
Accumulated Depreciation at the begening of the year	933,508	1,11
Less:		
Total Gross Block at the end of the year	6,894,905	5,963,92
Deletion		(32,61
Additions	930,977	5,992,94
Additions	1	





Schedule	: 12 Net Current Investme	nt			
Sr. No		Particulars		31.03.2022	31.03.2021
		***			
		Nit			
	Total in				
Sr. No	: 13 Deferred Tax Assets [/	Particulars		31.03.2022	31.03.2022
311100		1 41 51041413		31.03.2022	31.03.2022
		Nil			
	Total in		-		
	1				
	: 14 Long Term Loan & Ad				
Sr. No	Consults December	Particulars		31.03.2022	31.03.2021
.,	Security Deposit Other Deposit			5,093,628	4,993,642
III)	Loans & Advances to rela	ted parties			
(V)	Other Loans & Advances				
1 2	Bharatbhai V Patel Hetal Amit Patel			1	100,000
3	Meenaben B Pate			1 1	100,000
	Total in			5,093,628	5,293,642
Schedule	: 15 Other Non Current As	sets			
Sr. No		Particulars		31.03.2022	31.03.2021
		Nil			
	Total in				-
	: 16 Inventories				
Sr. No	Raw Material	Particulars		31.03.2022 27,800,342	31.03.2021 8,761,975
2	Finished Goods				76,970
3	Packing Material			10,026,278	1,466,411
4	Goods In Process  Total in			37,826,620	10,305,356
	: 17 Trade Receivables				
Sr. No	Others	Particulars		31.03.2022	31.03.2021
1	Others Unsecured, Considered Gr	ood:		54,367,108	B,779,067
	Advance Received paid to	supplier	_	7,269,140	7,386,436
	Total in			61,536,248	16,165,503
Schedule	: 18 Cash & Cash Equivaler	nt			
Sr. No		Particulars		31.03.2022	31.03.2021
1	Cash-in-Hand				
	Cash Balance			361,798	2,293,948
			Sub Total (A)	361,798	2,293,948
2	Bank Balance Axis Bank Ltd			2,242	134,138
	State Bank Of India			2,242	32,365
			Sub Total (B)	2,242	166,503
3	Fixed Deposit		(C)		
	Total [A + B+C]			364,040	2,460,451
	:19 Short Terms Loans an				74 07 7074
Sr. No	GST Receivable	Particulars		31.03.2022 36,493,325	31.03.2021 23,650,366
*	and the certains				
	Total in			36,493,325	23,650,366
	4240 2 2 2 2 2 2				
	:20 Other Current Assets	Particulare	1	31.03.2022	31.03.2021
Sr. No		Particulars		31.03.2022 74,866	31.03.2021 30,907
Sr. No 1 2	Prepaid Expense TDS Receivable	Particulars		74,866 100,011	30,907 9,116
Sr. No	Prepaid Expense	Particulars		74,866	30,907

						LTHCARE PRIVATE						
				Schedu	les Forming Integral P	art of the Balance Sh	eet as at 31st Mar	ch, 2022				
che	dule: 11- Property, Plant and Equipm	ent										
. Pro	pperty, Plant and Equipment											
				Gross	Block			Deprec	iation		Net Bio	ock
Sr. No	Particulars	Rate	01.04.2021	Addition during the year	Deduction during the year	31.03.2022	01.04.2021	Addition during the year	Deduction during the year	31.03.2022	WDV as on 31.03.2022	WDV as on 31.03.2021
	Tangible Assets											
1	Building	9.50%	22,215,513	2,173,159		24,388,672	2,593,296	690,829		3,284,125	21,104,547	19,622,217
2	Computer & Printer	63.16%	721,922	131,387		853,309	231,009	195,638		426,647	426,662	490,913
3	Electrical Fittings	25.89%	3,624,340	303,067	51,425	3,875,982	481,234	324,014		805,248	3,070,734	3,143,106
4	Furniture & Fixture	25.89%	5,963,928	930,977		6,894,905	933,508	562,264		1,495,772	5,399,133	5,030,420
5	GIDC Plot PF 20	0.00%	13,126,000	-		13,126,000					13,126,000	13,126,000
6	Plant & Machinery	18.10%	73,804,470	10,703,225	-	84,507,695	15,014,955	4,393,452		19,408,407	65,099,288	58,789,515
	TOTAL		119,456,173	14,241,815	51,425	133,646,563	19,254,002	6,166,197		25,420,199	108,226,364	100,202,17



Shopher befor 2.



# ANNEXURE - A Trade Payables

737112714112 71	Trouc rayas		
PARTICULARS	AMOUNT RS. 2021-22	AMOUNT RS. 2020-21	
A D Square Hvac System	17,183	17,221	
A-Line Box Packaging	245,551		
Aadarsh Enterprise	16,497	3,612	
Achal Pharma Pack	161,306		
Agile Diagnostics	-	23,128	
Air Validation System		11,000	
Ajanta Pharma Engineers	9,067	60,860	
Albatross Fine Chem (P) Ltd.		22,833	
Aditya Vikrambhai Patel		5,000	
Amit G Patel & Associates	25,000	25,000	
Amitbhai Govindbhai Patel	6,300		
Asha Agency	139,358	77,939	
Atlantis Trade Chem	116,218	102,129	
Aum Research Labs Private Limited		29,935	
Aurangabad Carbon Products Pvt Ltd	5,906		
Ayan Construction	42,651	42,651	
Alutech Packaging Pvt. Ltd.	1,555,277	669,803	
B.D.Industries	8,540	8,540	
Balaji Enterprise	856	29,604	
Bcm Corporation	2,256,807	25,00	
Bhargav Metal Product	61,050		
Bipin Offset Private Limited	19,512		
The state of the s	19,512	2,210	
Best Tec			
Bhavna Roadways	C 2C2	5,085	
Breath Air	6,262	6,262	
Bharat Trading Co.	11,451,504	7.020	
Care Process Instrument		7,936	
Cloudtail India Private Limited	6,043		
Cool Point	1 22 2 2	24,200	
Covalent Laboratories Private Limited	1,533,212		
Csir-National Chemical Laboratory	33,040	33,040	
Captech Systems		3,835	
D.V.Patel & Associates		7,725	
Delta Services	3,313	-	
Dhanuka Laboratories Limited	2,711,700		
Djk Industries	-	294,950	
Drishti Electricals	5,506	5,506	
Earth Syscom Pvt Ltd		1,496	
Elite System And Solutions		197	
Espee Pharmachem Pvt. Ltd.	19,256,269	1,598,918	
Everest Health Care	1,026,464		
Environ	24,300		
Expert Engineers	5,900		
Sher Payable		43.34	

Fluidpack	68,655	57,563
Ganesh Marketing	3,257	
Ganesh Sales	2,130	2,130
Gautam Tradelink	9,184	
Gayatri Enterprise	7,487	7,487
Gayatri Rubber Industries	7,841	12,607
Gmp Technical Solutuions Pvt Ltd.	-	383,952
Gorang International	16,075,415	3,990,630
Gujrat Industrial Devlopment Corporation		27,680
Hariom Sanitary	22,888	22,888
Heer Pharma Chem	528,310	242,483
Helios Concrew Pvt Ltd.	134,284	_
Hema Remedies Pvt. Ltd.	93,520	283,080
Harsiddhi Pharma Equipments	213,664	213,664
Hitech Healthcare Laboratory And Research Centre	6,956	-
Isbani Mehmudbhai Jamalbhai	117,170	117,170
Infinity Laboratories Private Limited	-	289,100
Jay Ambe Foils	384,964	-
Jaydevbhai Nautambhai Chavda	12,247	-
Juana Pharma	1,007,500	-
Jyoti Trading Co.	221,337	-
Kandarp Packaging	2,950	2,950
Kc Overseas Private Limited	3,662,725	-
Kesar Control System	10,030	3,404
Kijeka Engineers Private Limited	16,520	16,520
Kotiyark Corporation	116,820	12,154
Krina Engineers Pvt Ltd	4,021	4,021
Krishna Calibration & Services	77,760	32,096
Krishna Corrugation Industries	148,968	26,191
Labtronik		63,412
Letap Printpack	1,681,197	366,030
Mahalaxmi Pharma	40,120	-
Mahesh Desai	39,600	1.
Maintri Enterprise	480,444	1.
Malati	200,000	200,000
Manishkumar Madhubhai Patel	200,000	600,000
Manubhai Patel	91,008	91,008
Maxcheck Security & Allied Services	31,331	170,517
	14,425	14,425
Metalium Ceiling System  Mukesh H. Shah Co.	17,000	14,423
	17,000	7,062
Metro Machinery Suppliers		960
Navkar International Courier		5,015
Pacemaker Pharmachem		
Parshwa Enterprise		29,900
Patel Bharatbhai	-	46,896
Nij Solution	8,956	-
Parth Products	3,122	-
Patidar Electricals	2,189	3.655
Petrelplus Inc.	2,655	EL & ASSO



Den 6/22.

M.No. 197675 FRN No. 152837 A'BAD

Pharma Supply Agencies	12,961,757	6,014,795
Pharmachem Enterprise	1,230,243	29,500
Phone Wale	3,200	
Power Solutions	2,833	2,833
Prachin Chemical	236,000	
Parekh Solids Handling		45,000
Praj Print Pack	440,595	
Parth Engineers & Consultant	4,307	211,309
Pratham Enterprise	-	4,424
Pavan Electrical & Hardware	4,210	
Rakesh Chemicals Chhatral	53,872	294,673
Ramdoot Packaging	380,940	124,333
Rettenmaier India Private Limited		29,500
Rishabh Life Science Pvt Ltd		300,900
Sai Krupa Industries		25,016
Sangeeta Consultancy		29,900
Satyam Stationery Mart	101,096	100,116
Shah Consultancy	17,700	2,950
Shah Tc Distribution Llp	5,735,578	
Shreeji Bottle Trading Company	317,768	3,590
Sneha Medicare Pvt Ltd	1,746,400	-,
Sotac Research Pvt Ltd	-	4,720
Sun Enterprise	30,322	
Sunrise Enterprise		6,490
Sunrise Packing Industries	166,549	166,397
Suren Healthcare	42,443	55,810
Sureshbhai G Patel	6,533	6,533
Swastik Glass Industries	8,340	8,340
Shiva Trading Co.	20,650	0,510
Swati Switchgears (India) Pvt.Ltd	170,140	170,140
Tech India Infosolution Pvt Ltd	3,363	270,240
Tech Solutions	2,583	2,583
Technolab Sales & Services	2,500	25,400
	635,163	163,726
Trio Pharma Chem	3,852,104	1,390,683
Unique Product	1,311,110	1,390,063
Uniworth Enterprises Llp	36,580	7,080
V.M.Services	50,000	50,000
V.R.Patel & Associates Velnex Pharma	30,000	33,040
Vijay Packaging	1,213,206	372,331
	37,000	
Vijay Sales		37,000
Vishal Enterprise	184,080	58,410
Vikram Thermo (India) Ltd	339,212	91,450
Vodafone Idea Limited	3,417	3,417
Wave Analytical & Research Center	6,912	104,870
Advance From Debtors		
Ronak Healthcare Pvt Ltd	500,000	
Symwell Pharmaceuticals	10,000	1518480



Der 1 6/82-

M.No. 197675 FRN No. 152837 A'BAD

Advance Consider From Agency		
A STATE OF THE STA		
Patel Manishkumar Madhubhai-Huf Security Deposit	1,200,001	
Shantaben Madhubhai Patel Security Deposit	2,000,000	
Smeet Manishkumar Patel Security Deposit	700,000	
Hetal Hardik Patel Security Deposit	500,000	
Manishkumar Madhubhai Patel Security Deposit	600,000	
Meenaben Gopalbhai Patel Security Deposit	1,500,000	
Jashiben Shivrambhai Patel Security Deposit	1,999,999	
Prahaladbhai Manilal Patel Security Deposit	2,000,000	
Priyankaben Mehulkumar Patel Security Deposit	5,000,100	
Saral Pharma Security Deposit	900,000	
Suchiben Kalpeshkumar Security Deposit	500,000	
Sushilaben Chunilal Solanki Security Deposit	1,000,000	
Hardik Govindbhai Patel Security Deposit	1,000,000	
Kapilkumar Chunilal Patel Security Deposit	1,000,000	
TOTAL	118,085,547	27,030,336



osen lefoz.



# B Trade Payables Aging Schedules

As at 31st March,2022

	01	Outstanding for following periods from						
Particulars	Less than 1 Year	1-2 Years	2-3 Years	More than 3 years	Total			
MSME								
Others	118,085,547				118,085,547			
Disputed Dues-MSMEs					-			
Disputed Dues-Others					-			

As at 31st March,2021

	Outstanding for following periods from						
Particulars	Less than 1 Year	1-2 Years	2-3 Years	More than 3 years	Total		
MSME							
Oothers	26,973,153	57183			27,030,336		
Disputed Dues-MSMEs					-		
Disputed Dues-Others					-		



THCARAT CONTRACTOR OF THE SECOND SECO

en Ho

# SOTAC HEALTHCARE PRIVATE LIMITED

Δ

# ANNEXURE - B Adavance to Suppliers

PARTICULARS	AMOUNT RS. 2021-22	AMOUNT RS. 2020-21	
Aurangadabad Carbon Products		(1,820)	
Adroit Machinery	90,500		
Agile Diagnostics	65,313		
Anjali Solution	150,000		
Apikor Corporation	951,000	(800,000)	
Aum Research Labs Private Limited	23,401		
Ausl Pharma	915		
Apikore Buildcon	5,637,889		
Brahmani Steel		(100,000)	
Biocare Formulation	590		
Dpb Management Services Pvt Ltd	100,000		
Darshan Industries		(288,711)	
Egniol Services Private Limited		(7,080)	
Foot Print	20,000		
Gmp Technical Solutuions Pvt Ltd.	26,727		
Girishbhai Rambhai Patel		(1,368)	
Glacier Tek Service		(15,340)	
Lupin Limited	97,000		
Umiya Enterprise	105,806		
Helios Concrew Pvt Ltd.		(45,769)	
Hinaben Vishnubhai Prajapati		(5,100)	
Indian Pharmacopoeia Commission		(12,544)	
Kamal Corporation		(88,206	
Lupin Limited		(97,000	
Maruti Hardware & Plywood		(28,225)	
Mukesh D Patel		(8,500)	
Nij Solution		(78,191)	
Pramukh Trading		(27,494)	
Pzarchstudio		(88,500)	
Pavan Electrical & Hardware		(9,355	
Shiv Engineering Co.		(96,517	
Sukhdeybhai B Panchal		(165,000)	
Shiva Trading Co.		(31,493	
Tirupati Engineering		(88,500)	
Umiya Enterprise		(64,500	
Yasin R Multani		(92,800	
Navjivan Medical Store		247,200	
Purple Inc.		15,351	
Other Director Payable		(194,279	
kesh D Patel		(2,695	
TOTAL	7,269,140	7,386,430	

Del

6/12



# SOTAC HEALTHCARE PRIVATE LIMITED

Δ

# ANNEXURE - C Trade Receivables

	PARTICULARS	AMOUNT RS. 2021-22	AMOUNT RS. 2020-21
Aarsh Remedies	Pvt. Ltd.	251,776	
Acme Pharmace	uticals	1,593,766	
Aerodeep Health	ocare	235,921	336,840
Aptus Pharma Pv	rt. Ltd.	103,250	
Biothemis Pvt. Lt	d.	150,456	
Brussels Laborat	ires Pvt. Ltd.	879,623	
Curever Pharma	Private Limited	5,696,567	
Curis Lifescience	s Pvt Ltd	15,567	
Decent Pharmac	euticals	465,822	251,454
Dls Export		474,432	
Ecomac Pharma	Llp	608,260	420,147
Eshar Pharmacei	uticals Pvt. Ltd.		224,059
Endurance Lifeso	ience	372,696	
Estrellas Life Scie	ences Pvt. Ltd.	255,518	
Excel Biolife Pvt.	Ltd.	1,020	
Ghc Drugs And P	harmaceuticals Private Limited	301,840	
Green Cross Ren	nedies	2,512	1,743
Healthonicdrug I	Pharmaceutical Company	303,346	
Harvin Pharmace	euticals		559
Hertz Biotech			108,886
Helvetius Life Sci	ence	80,464	
Inqure Health Inc	dia Private Limited	30,172	
J.P. Life Science I	Pvt. Ltd.	2,042,487	
Kaps Three Life S	ciences Private Limited	1,404,922	
Karnavati Pharm	aceuticals	300,014	
Kentossa Pharma		95,004	
Lincoln Pharmac	euticals Ltd.	6,261,008	888,736
Macline Pharma	ceuticals	104,104	
Nenshi Healthca	re	164,862	155,658
Neuron Pharma	Private Limited	1,486,860	512,706
New Life Medica	ls Private Limited	7,070,191	
Nikol Formulatio	n Pvt. Ltd.	413,196	413,196
Nikol Healthcare	Pvt. Ltd.	985,970	985,970
Nisarg Pharma		137,921	
Noronic Pharma	ceutical Pvt Ltd.	480,689	
Olcare Laborator	ries Pvt. Ltd.	3,777,937	2,080,737
Other Receivbab	ile		33,210
Parth Pharma Lif	e Llp	339,716	160,989
Sai Moreshwar F	Pharmaceuticals Pvt. Ltd.	88,054	3,014
Sapling Pharmac	euticals	333,967	
Sentonssa Welln	ess Pvt. Ltd.	3,794	146,68
Shankus Acme P	harma Private Limited	1,265,078	
Shantam Lifescie	ences	362,377	
Sotac Pharmace	uticals Pvt. Ltd.	101,207	
Sotac Research I	Pvt Ltd	55,286	
Stallion Laborato	ories Private Limited	2,398,691	
Sunrest Lifescier	nce Pvt. Ltd.	1,669,885	1,011,85
reatsure Pharm		63,840	

THC 40 NAMES OF THE PARTY OF TH

Bley


b/2

M.No. 197675 FRN No. 152832W A'BAD

TOTAL	54,367,108	8,779,067
Zota Health Care Limited	6,774,092	
Wexcare Pharmaceutical	953,032	
Wellogen Pharma Pvt. Ltd.	713,213	
Varun Medical Agency	203,234	
Uniza Healthcare Llp	884,107	
Unicor Pharmaceuticals Llp	1,609,362	134,528
Treatwell Pharma		739,323
Swejer Medicare		168,773









# B Trade Receivables Aging Schedules As at 31st March, 2022

	Outstanding for following periods from due date of payment							
Particulars	Less than 6 Month	6 Months- 1 γear	1-2 Years	2-3 Years	More than 3 years	Total		
Undisputed Trade Receivables-Considered Good	60061633.08	1574615				61636248		
Undisputed Trade Receivables-Considered Doubtful						0		
Disputed Trade Receivables-Considered Good					7/10	0		
Disputed Trade Receivables-Considered Doubtful						0		

# As at 31st March, 2021

	Outstanding for following periods from due date of payment						
Particulars	Less than 6 Month	6 Months- 1 year	1-2 Years	2-3 Years	More than 3 years	Total	
Undisputed Trade Receivables-Considered Good	15,771,173	394330				16165503	
Undisputed Trade Receivables-Considered Doubtful						0	
Disputed Trade Receivables-Considered Good						0	
Disputed Trade Receivables-Considered Doubtful						0	

0.00



Delut by 2



# SOTAC HEALTHCARE PRIVATE LIMITED

Schedules Forming Part of the Profit & Loss Accounts as at 31st March 2022

Schedule:	21	Revenue	from (	Operations
-----------	----	---------	--------	------------

Sr. No	Particulars	31.03.2022	31.03.2021
1	Net Sales	228,537,539	56,855,696
	Total in	228,537,539	56,855,696

### Schedule : 22 Other Income

5r. No	Particulars	31.03.2022	31.03.2021
1	Interest on Deposits	111,096	142,552
2	Interest on Refund	19,376	_
3	Subsidy Income	847,146	
4	Depreciation A/c	12,305,066	
5	Providend Fund Subsidy	75,535	*
	Total in	13,358,219	142.552

#### Schedule: 23 Cost of Material Consumed

Sr. No	Particulars		31.03.2022	31.03.2021
a)	PURCHASES OF RAW MATERIALS AND ST	TORES		
1	Purchase		217,370,317	66,275,44
		Sub-total (a)	217,370,317	66,275,447
b)	DIRECT/PRODUCTIONS EXPENSES			
1	Packing and Forwarding Charges		287,515	11,599
2	Apron and Uniform Expense		82,322	70,729
3	Cylinder Charge		211,700	244,200
4	Lab Chemical Purchase		99,910	106,519
5	Laboratory & Testing Expense		75,045	211,49
5	Product Permission Expense		356,200	68,390
7	Consumable & Store Expense		1,368,920	267,553
В	Production Expense		28,011	8,625
		Sub-total (b)	2,509,624	989,110
	Total in		219,879,941	67,264,557

## Schedule: 24 Purchase of Stock in Trade

Sr. No	Particulars	31.03.2022	31.03.2021
Total in			

## Schedule: 25 Change in Inventories

Sr. No	Particulars	31.03.2022	31.03.2021
1	Opening Stock	10,305,356	
2	Closing Stock	37,826,619	10,305,356
	Total in	(27,521,264)	(10,305,356)

### Schedule: 26 Employement Benefit Expenses

Sr. No	Particulars	31.03.2022	31.03.2021
1	Salaries, Bonus, PF & ESIC	3,807,823	2,318,574
2	Staff Welfare Expense	745,280	27,100
3	Director Remuneration	2,500,000	
4	Bonus Expense	513,864	
	Total in	7,567,967	2,345,674

### Scedule : 27 Financial Cost

Sr. No	Particulars	31.03.2022	31.03.2021
1	Interest to Bank:		
	Interest on Loan-Term Loan	3,500,648	6,605,183
	Interest on Loan-Cash Credit	1,939,739	
	Interest on Other (Unsecured Loan)	5,120,137	943,98
2	Others		
	Bank Charges	57,130	10,85
	Loan Processing Charges	90,225	115,72
	Loan Transfer Charges	541,226	
	Total in	11,249,105	7,675,74

# Schedule: 28 Depreciation & Amortised Cost

Sr. No	Particulars	31.03.2022	31.03.2021
1	Depreciation	5,166,197	15,935,604
2	Preliminary Expenses W/O		
	Total in	6,166,197	15,935,604

Sr. No	Particulars	31.03.2022	31.03.2021
1 A	udit Fees	100,000	52,410
2 P	rofessiona Fee	383,061	136,75
3 0	Office Expense	54,740	119,77
4 R	OC Expense	5,400	25,10
5 E	lectric Bills Exp	3,915,084	2,583,98
6 0	ommission Exp	546,730	
7 F	reight Expense	112,620	75,24
8 K	asar & Vatav	61,330	27,43
9 L	abour & Wages	5,020,947	967,22
10 L	egal Expenses	407,250	29,90
11 P	etrol & Fuel Expense	133,030	42,26
12 R	lepair and Maintenace Exp	1,402,164	3,423,06
13 R	lepairs & Maintaing to Building	345,495	1,217,67
	Memberahip Fee	15,000	-,,
15 5	ecurity Expenses	228,072	244.92
	tationery & Printing Expense	341,853	183,86
	ea & Refreshment Expense	49,695	200,00
	ransport Expense	981,380	
19 V	Vater Expense	155,164	92,38
20 5	oftware-Renewal Expense	60,000	12,83
21 T	elephone & Internet Expense	70,823	72,15
22 P	F & ESIC Expense	267,363	278,22
23 A	dvertisement Expense	110,000	37,49
24 C	alibration Expense	72,000	48,20
25 C	omputer & Maintainance Expense	17,850	55,34
	ourier Expense	9,148	2,30
27 10	nsurance Expense	273,878	375,09
28 C	onsultancy Charges	236,455	452,29
	actory Expense	50,000	242,35
30 H	louskeeping & Garden Expense	245,838	121,22
31 N	Medical Expense	116,742	21,60
32 N	disc Expense	376,278	13,57
33 P	enalty Charge		1,00
34 In	nterets on TDS/TCS	1,857	61
35 F	oreign Exchange Loss	135,887	
	ent Expense (Machinery)	33,000	
	icense and Certificate Fees	37,809	
	ravelling Exp	313,077	
Т	otal in	15,687,020	10,956,30



Der



# SOTAC HEALTHCARE PRIVATE LIMITED CIN- U369992019PTC106282

# **Significant Accounting Policies**

NOTE: 30

# A. Basic of Preparation of Financial Statements

The financial statement have been prepared under the historical cost convention on going concern basis in accordance with the generally accepted accounting principles in India and mandatory accounting standards issued by the Institute of Chartered Accountants of India and the applicable accounting standards notified under the Companies (Accounting Standards) Rules, 2006. All income and expenditures having material bearing on the Financial Statements are recognized on accrual basis.

### B. Use of Estimates

The preparation of financial statement requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the results are known\materialized.

# C. Own Property, Plant and Equipment

Property, Plant and Equipment are stated at cost net of modvat / cenvat less depreciation. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the Property, Plant and Equipment are capitalized.

## D. Leased Assets

Operating Lease: Rentals are expensed with reference to Leased terms and other considerations.

# E. Preliminary Expenses

Preliminary Expenses are allocated to the cost of building and machineries on the basis of cost incurred.

### F. Depreciation

Depreciation is provided, on a Pro-rata basis, from the date of the Assets have been installed and put to use, on Straight Line Method. Depreciation is provided on the basis of useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.

# Change in the Method of Provision of Depreciation:

In the Previous financial year 2020-21, the Company has provided Depreciation on Property, Plant and Equipment on WDV Method. And In this Current Financial year the Company has changes its Depreciation method from WDV to on the basis of

- Der

6/12

1

useful life of the assets as prescribed in Schedule II to the Companies Act, 2013.. Due to this effect Net Profit has increased by Rs. 1,23,05,066/-.

# G. Impairment of Assets

During the year, the carrying cost of assets does not exceed its recoverable value, Hence Impairment Profit/Loss is not charged to Profit and Loss Account.

# H. Foreign Currency Transactions

- a) Transactions denominated in foreign currencies are normally at the exchange rate prevailing at the time of the transaction.
- b) Any income or expense on account of exchange difference either on settlement or on translation is recognized in the profit and loss account except in cases where they relate to acquisition of fixed assets in which case they are adjusted to the carrying cost of such assets.

## I. Inventories

Items of inventories are measured at lower of cost or net realizable value. Cost of inventories comprises of all cost of purchase cost of conversion and other costs incurred in bringing them to their respective present location and condition. Cost of raw materials, stores and spares, packing materials and Fuel are determined on weighted average basis. Cost of work-in-progress is determined on absorption costing method. Valuation of Finished Goods is cost or net realization value, whichever is less.

## J. Turnover

Sales Turnover includes sale of Goods at Head Office and Branches, excludes Central Goods and Services tax.

# K. Goods and Services Tax

Goods and service Tax is not charged to Profit and Loss Account.

# L. Employee Retirement benefits

Company's contribution to Provident fund is charged to Profit and Loss Account. Provision for Leave encashment liability is not accounted as the company is not liable for any leave encashment liability as on 31st March, 2022.

Company has not made any provision for gratuity and accounted on paid basis..

## M. Borrowing Costs

Borrowing costs that are attributable to the acquisition, construction of qualifying assets are capitalized as part of the cost of such assets till the month in which the assets is ready for use. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to Profit and loss Account as an expense in the period in which these are incurred.

N. Provision for Current and Deferred Tax

Provision for current tax is made after taking in to consideration benefits admissible under the provisions of the Income Tax Act, 1961. Deferred Tax resulting from "

Der 6/2 2 -

2

Timing Difference "Between Book and Taxable Profit is accounted for using the Tax rates and laws that have been enacted or substantively enacted as on the Balance sheet date.

# O. Provision, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities\Assets are neither recognized nor disclosed in the financial statements.

P. The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards notified under the Companies Act (Companies (Accounting Standards) Rules, 2021) Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company."

As per our report of even date attached.

For, Amit G Patel & Associates

M. No. 197675

**Chartered Accountants** 

FRN. 152837W

CA. Amit G Patel

Proprietor

Mem No. 197675

UDIN: 22197675AWVUYE3101

For, SOTAC HEALTHCARE PVT. LTD. CIN - U369992019PTC106282

--

Sharad Patel
Director

DIN No-07252252

Kamlesh Patel

Director

DIN No-08343809

# SOTAC HEALTHCARE PRIVATE LIMITED CIN- U369992019PTC106282

## **Notes on Accounts**

Schedule: 31

1. The previous year figures have been reworked, regrouped, rearranged and reclassified wherever necessary. Accordingly, amounts and other disclosures for the preceding year are included as an integral part of the Current year financial statements and are to be read in relation to the amounts and other disclosures relating to the current year.

The Cash Credit Account Facility with the Axis bank is Shown under the Head "Long Term Borrowings" due to bundled Credit Facility (Other Term Loans) availed from the Axis Bank. If the Cash Credit Account balance shown under the Head "Short term Borrowings" then the Balance to that extent is increase under the head "Short term Borrowings "and reduce that extent under the head "Long Term Borrowings".

- 2. The Fixed assets have not been revalued during the year.
- 3. The Semi-Finished goods have been valued by including the direct production related Overheads. The Raw Material cost is calculated by including direct expenses related to raw material purchase e.g. raw material transportation exps.

4. Segment Reporting:

The company does not have more than one reportable segment, accordingly pursuant to AS-17 on Segment Reporting issued by the ICAI, Hence Segmental information is not required to provide.

# 5. Value of the Raw Material Consumed:

	(In Rupees)	
	2021-22	2020-21
Indigenous	21,73,70,316.00	6,62,75,447.00
Imported	NIL	NIL

**6.** As per Accounting standard 18, issued by the Institute of Chartered Accountants of India, The disclosures of transactions with the related parties as defined in the Accounting Standard are given below:

Name of Party	Relation	Nature of transaction	Amount (Rs.)
Chetanbhai Patel	Director	Remuneration	5,00,000/-
Babubhai Mali	Father of Director	Interest	55,632/-
Bhavanaben M Patel	Sister of Director	Interest	3,00,000/-
Dasharathbhai R Patel	Father of Director	Interest	3,73,206/-
Kalpeshbhai Mali	Brother of Director	Interest	27,816/-
Mukeshbhai Patel	Director	interest	2,79,808/-
Narmadaben Patel	Mother of Director	Interest	8,28,750/-

DAN

b/42.

1

Sarojben Patel	Sister of Director	Interest	3,00,000/-
Tejalben Mali	Mother of Director	Interest	27,816/-
Varshaben Solanki	Sister of Director	Interest	1,06,731/-
Kamlesbhai Patel	Director	Remuneration	5,00,000/-
Sharadbhai Patel	Director	Remuneration	5,00,000/-
Vishalbhai Patel	Director	Remuneration	5,00,000/-
Dineshbhai Gelot	Director	Remuneration	5,00,000/-
Sotac Pharamaceuticals Pvt. Ltd.	Significant Influence by Directors	Loan Taken	1,71,40,637/-
Sotac Pharamaceuticals Pvt. Ltd.	Significant Influence by Directors	Reduction of Investment in Equity shares	20,40,000/-

The Company has one type of inter company transaction with the Sotac Pharamceuticals Pvt. Ltd. In the nature of RM P M and other general purpose expenses transactions at Cost.

7. Earnings per Share (EPS) - The numerator and denominator used to calculate Basic and Diluted Earnings per Share:

	(Amount in Rs.)		
Particulars	2021-22	2020-21	
Profit attributed to the equitable shareholders used as numerator – (A)	63,55,854/-	-3,68,74,278	
The weighted average number of equity shares outstanding during the year used as denominator – (B)	57,15,000	40,00,000	
Basic/ Diluted Earnings Per Share (Rs.) - (A)/ (B)	1.11	-9.22	

8. Auditors' Remuneration is made up of:

		(Amount in Ks
F.Y. Year	2021-22	2020-21
Audit Fees	1,00,000/-	52,410/-

9. In the Current Financial year, Sotac Pharmaceuticals Pvt. Ltd. (Holding) Company has sold their entire Shareholding of 51 % in the Company.

Due to this as on 31/03/2022 their holding in the Company is reduced to 0%.

10. As per information given to us by the Management The Company has not received any MSME status Certificates from Suppliers ,hence, it is not possible ro disclose details relating to Micro, Small and Medium Enterprises.

11. Subsidy received from the Government is recognised on actual recipt basis only.

Sterl

6/2 L-

M.No. 197675

# **Additional Regulatory Disclosures:**

- 1. As per information given to us by the Management ,The Title Deeds of Immovable Properties are held in the name of the Company.
- 2. As per information given to us by the Management ,The Company has not Revalued its Property, Plant and Equipment.
- 3. Loans to Directors, KMPs, Promoters and Related parties are as below:


Type of Borrowers	Amount of Loan Outstanding	% of Total Loans and advances
Promoters	Nil	Nil
Directors	Nil	Nil
KMPs	Nil	Nil
Related parties	Nil	Nil

- 4. As per information given to us by the Management, the company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken at the balance sheet date,
- 5. As per information given to us by the Management, there is no any Capital Work in Progress.
- 6. As per information given to us by the Management, there is no any Intangible Assets under Development.
- 7. As per information given to us by the Management, There is no any proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder,
- 8. As per information given to us by the Management ,the Company has borrowings from banks or financial institutions on the basis of security of current assets and -
- a. Quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts.

9. As per information given to us by the Management, a company is not a declared wilful defaulter by any bank or financial Institution or other lender of the Association of the second of the second

Den 1/62

- 10. As per information given to us by the Management, the company has not any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956,
- 11. As per information given to us by the Management ,There is no any charges or satisfaction yet to be registered with Registrar of Companies.
- 12. As per information given to us by the Management ,the company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017,
- 13. As per information given to us by the Management ,There is no any Scheme of Arrangements has been incurred in the year.
- 14. A. As per information given to us by the Management ,The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries;
- B. As per information given to us by the Management, The company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- 15. As per information given to us by the Management, The Company has not been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- 16. As per information given to us by the Management, the company has not covered under section 135 of the companies act.





17- Ratio

No.	Name of Ratio	Formula	Ratio in	31-03-2022	31-03-2021	% of Variance	Reason for variance in excess of 25 %
1	Current Ratio	Current assets Current Liabilites	Times	1.14	1.90	(39.71)	Refer Note-A
2	Debt-Equity ratio	Total Borrowings Shareholder's Equity	Times	5.33	(42.64)	(112.51)	Refer Note-B
3	Debt Service Coverag Ratio	Earnings available for Debt Interest +Installments	_ Times	2.11	(1.73)	(222.30)	Refer Note-C
4	Return on equity Ratio	Net Profit after tax Shareholder's Equity	%	31.20	(1,177.43)	(102.65)	Refer Note-D
5	Inventory Turnover Ratio	Cost of Goods Sold Average Inventory	Times	7.99	5.53	44.61	Refer Note-E
6	Trade Receivable Turnover Ratio	Credit Sales Average Trade Receivables	Times	7.24	12.95	(44.12)	Refer Note-F
7	Trade Payable Turnover Ratio	Credit Purchases Average Trade Payables	Times	3.04	3.26	(6.79)	
8	Net Capital Turnover Ratio	Sales Working Capital	Times	13.29	2.28	482.12	Refer Note-G
9	Net Profit Ratio	Net Profit after Tax Sales	_ %	2.78	(64.86)	(104.29)	Refer Note-H
10	Return on Capital Exployed	Earnings Before Interest and taxes Capital Employed	_ %	14.82	(22.39)	(166.18)	Refer Note-I
11	Return on Investment	Earnings Before Interest and taxes Average Total Assets	_ %	9.37	(20.74)	(145.18)	Refer Note-J

# Notes to Ratio-

- A- Primarily Due to delaying recovery due to Pandemic effect.
- B- Primarily Due to improvement in the Profitability.
- C- Primarily Due to improvement in the Profitability
- D- Primarily Due to improvement in the Profitability
- E- Primarily Due to increase of Cost of Goods sold
- F- Primarily Due to Improvement in Credit Sales.
- G- Primarily Due to Improvement in Credit Sales...
- H- Primarily Due to improvement in the Profitability.
- I- Primarily Due to improvement in the Profitability.
- J- Primarily Due to improvement in the Profitability.

18. As per information given to us by the Management the Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

As per our report of even date attached.

For, Amit G Patel & Associates

**Chartered Accountants** 

FRN :152837W TEL & AS

M.No. 197675 FRN No. 152837W

RN No. 152837

CA. AMIT G PATEL

Proprietor

Mem No. 197675

UDIN: 22197675AWVUYE3101

For, SOTAC HEALTHCARE PRIVATE LIMITED. CIN NO-U36999GJ2019PTC106282

Der

Sharad Patel
Director

DIN No-07252252

Kamlesh Patel

Director

DIN No-08343809

Date: - 02/09/2022 Place:-Ahmedabad